Skip to main content

Table 2 Univariate Analyses of tumor-related death among 568 patients using the ENETS, 8th AJCC, 7th AJCC and m7th AJCC staging systems including four tumor stages for pNECs

From: Validation and modification of staging Systems for Poorly Differentiated Pancreatic Neuroendocrine Carcinoma

TNM staging systems

Median OS (months)

HR (95%CI)

P

ENETS

 I

90.0

1

 

 II

40.0

3.28 (0.77–13.98)

0.11

 III

48.0

2.22 (0.54–9.13)

0.27

 IV

7.0

8.92 (2.21–35.92)

0.002

8th AJCC

 I

62.0

1

 

 II

138.0

0.70 (0.38–1.26)

0.23

 III

15.0

1.73 (0.93–3.21)

0.08

 IV

7.0

3.70 (2.26–6.06)

< 0.001

7th AJCC

 I

90.0

1

 

 II

40.0

1.08 (0.60–1.93)

0.79

 III

13.0

2.14 (0.98–4.67)

0.06

 IV

7.0

4.36 (2.58–7.36)

< 0.001

m7th AJCC

 I

90

1

 

 II

31

1.24 (0.74–2.07)

0.41

 III

13

2.31 (1.12–4.75)

0.02

 IV

7

4.70 (3.05–7.24)

< 0.001

  1. Abbreviations: AJCC American Joint Committee on Cancer; ENETS European Neuroendocrine Tumor Society; m7th AJCC modified 7th AJCC; pNECs poorly differentiated pancreatic neuroendocrine carcinomas; OS overall survival; HR hazard ratio; CI confidence interval